Tucatinib + Trastuzumab + Capecitabine
Pre-clinicalCompleted 0 views this week 0 watching💤 Quiet
Interest: 26/100
26
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Metastatic HER2+ Advanced Breast Cancer
Conditions
Metastatic HER2+ Advanced Breast Cancer
Trial Timeline
May 7, 2025 → Sep 25, 2025
NCT ID
NCT06961331About Tucatinib + Trastuzumab + Capecitabine
Tucatinib + Trastuzumab + Capecitabine is a pre-clinical stage product being developed by Pfizer for Metastatic HER2+ Advanced Breast Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT06961331. Target conditions include Metastatic HER2+ Advanced Breast Cancer.
What happened to similar drugs?
20 of 20 similar drugs in Metastatic HER2+ Advanced Breast Cancer were approved
Approved (20) Terminated (8) Active (0)
Hype Score Breakdown
Clinical
3
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06961331 | Pre-clinical | Completed |
| NCT04721977 | Phase 2 | Active |
Competing Products
20 competing products in Metastatic HER2+ Advanced Breast Cancer